Study of people living with HIV and Taking Certain Medications
Bictegravir in the Elderly Living with HIV: Impact of Polypharmacy and Multimorbidity
This study enrolls people who are HIV positive who are taking certain medication. If a person take Stribilid® or Genvoya®, there may be changes in the way their body uses or removes other medications. We want to study another approved treatment, Biktarvy®, that we believe is less likely to affect how the body handles other medications that a person is currently taking. This switch may improve quality of life.
You will be in this study for about 24 weeks. You will switch your current therapy from Genvoya® or Stribild® to Biktarvy® and complete three surveys over the course of the study. You will attend in-person visits and physical exams and give blood and urine samples. Study takes place at Evergreen Health in Buffalo, NY.
Although (ART), when used concurrently with certain medications, has an increased risk of potential drug to drug interactions (PDDI), studies have suggested a low DDI profile of Biktarvy. Our objective of the study: is to evaluate such benefits of Biktarvy by assessing the evaluation of polypharmacy, PDDI, its effect on health-related quality of life, and adherence of HIV-infected subjects. Our Hypotheses: Is that by switching from Genvoya or Stibilid to Biktarvy we will decrease the number of PDDI, and improve patients health-related quality of life in older adults on polypharmacy.
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
-Adults ages 18+.
-Positive for HIV.
-Taking current antiretroviral therapy GenvoyaTM or StribildTM for HIV-1 infection.
-Taking at least 1 or more other prescription medications.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.